Browse F3

Summary
SymbolF3
Namecoagulation factor III (thromboplastin, tissue factor)
Aliases CD142; TFA; CD antigen CD142; Thromboplastin; Coagulation factor III; Tissue factor
Chromosomal Location1p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Membrane Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 2: Secreted
Domain PF09294 Interferon-alpha/beta receptor
PF01108 Tissue factor
Function

Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0002526 acute inflammatory response
GO:0002541 activation of plasma proteins involved in acute inflammatory response
GO:0002543 activation of blood coagulation via clotting cascade
GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0007596 blood coagulation
GO:0007598 blood coagulation, extrinsic pathway
GO:0007599 hemostasis
GO:0010640 regulation of platelet-derived growth factor receptor signaling pathway
GO:0010641 positive regulation of platelet-derived growth factor receptor signaling pathway
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0016485 protein processing
GO:0030193 regulation of blood coagulation
GO:0030194 positive regulation of blood coagulation
GO:0030335 positive regulation of cell migration
GO:0032103 positive regulation of response to external stimulus
GO:0040017 positive regulation of locomotion
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043491 protein kinase B signaling
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045862 positive regulation of proteolysis
GO:0048008 platelet-derived growth factor receptor signaling pathway
GO:0048514 blood vessel morphogenesis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050820 positive regulation of coagulation
GO:0050878 regulation of body fluid levels
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0050926 regulation of positive chemotaxis
GO:0050927 positive regulation of positive chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0051604 protein maturation
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0061041 regulation of wound healing
GO:0072376 protein activation cascade
GO:0072378 blood coagulation, fibrin clot formation
GO:0090303 positive regulation of wound healing
GO:1900046 regulation of hemostasis
GO:1900048 positive regulation of hemostasis
GO:1901342 regulation of vasculature development
GO:1903034 regulation of response to wounding
GO:1903036 positive regulation of response to wounding
GO:1904018 positive regulation of vasculature development
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000147 positive regulation of cell motility
GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function GO:0002020 protease binding
GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0004896 cytokine receptor activity
GO:0005543 phospholipid binding
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0009897 external side of plasma membrane
GO:0031233 intrinsic component of external side of plasma membrane
GO:0098552 side of membrane
GO:1905286 serine-type peptidase complex
GO:1905368 peptidase complex
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
Reactome R-HSA-140834: Extrinsic Pathway of Fibrin Clot Formation
R-HSA-140877: Formation of Fibrin Clot (Clotting Cascade)
R-HSA-109582: Hemostasis
Summary
SymbolF3
Namecoagulation factor III (thromboplastin, tissue factor)
Aliases CD142; TFA; CD antigen CD142; Thromboplastin; Coagulation factor III; Tissue factor
Chromosomal Location1p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between F3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolF3
Namecoagulation factor III (thromboplastin, tissue factor)
Aliases CD142; TFA; CD antigen CD142; Thromboplastin; Coagulation factor III; Tissue factor
Chromosomal Location1p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of F3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolF3
Namecoagulation factor III (thromboplastin, tissue factor)
Aliases CD142; TFA; CD antigen CD142; Thromboplastin; Coagulation factor III; Tissue factor
Chromosomal Location1p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of F3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.1730.0233
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.7810.122
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7170.384
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0270.967
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7130.734
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8420.756
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.170.763
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2290.828
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5710.604
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5270.233
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 283.3820.0337
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5220.019
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of F3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolF3
Namecoagulation factor III (thromboplastin, tissue factor)
Aliases CD142; TFA; CD antigen CD142; Thromboplastin; Coagulation factor III; Tissue factor
Chromosomal Location1p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of F3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolF3
Namecoagulation factor III (thromboplastin, tissue factor)
Aliases CD142; TFA; CD antigen CD142; Thromboplastin; Coagulation factor III; Tissue factor
Chromosomal Location1p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of F3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by F3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolF3
Namecoagulation factor III (thromboplastin, tissue factor)
Aliases CD142; TFA; CD antigen CD142; Thromboplastin; Coagulation factor III; Tissue factor
Chromosomal Location1p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of F3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolF3
Namecoagulation factor III (thromboplastin, tissue factor)
Aliases CD142; TFA; CD antigen CD142; Thromboplastin; Coagulation factor III; Tissue factor
Chromosomal Location1p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of F3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolF3
Namecoagulation factor III (thromboplastin, tissue factor)
Aliases CD142; TFA; CD antigen CD142; Thromboplastin; Coagulation factor III; Tissue factor
Chromosomal Location1p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between F3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolF3
Namecoagulation factor III (thromboplastin, tissue factor)
Aliases CD142; TFA; CD antigen CD142; Thromboplastin; Coagulation factor III; Tissue factor
Chromosomal Location1p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting F3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting F3.
ID Name Drug Type Targets #Targets
DB00036Coagulation factor VIIa Recombinant HumanBiotechF10, F3, F7, GGCX, HPN, TFPI6
DB072072-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINESmall MoleculeF3, F72
DB07247[2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREASmall MoleculeF3, F72
DB08232[5-(5-Amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acidSmall MoleculeF3, F72
DB13150Coagulation factor VII humanBiotechF10, F3, F93